Literature DB >> 1069596

A simplified in vitro classification for prognosis in adult acute leukemia: the application of in vitro results in remission-predictive models.

G Spitzer, K A Dicke, E A Gehan, T Smith, K B McCredie, B Barlogie, E J Freireich.   

Abstract

Previous classification in vitro of adult acute leukemia incorporating morphology has been complex and difficult to understand. We have devised a simplified classification based solely on leuekemic proliferation in vitro. Seventy-six patients with adult acute leukemia previously untreated were included in this study and received identical chemotherapy. Three groups were recognized. The complete remission rate was 76% in the 21 patients with no leukemic growth in vitro (Group 1), 75% in 36 patients with leukemic cell growth but aggregates of 20 cells or less (Group 2), and only 21% in the 15 patients with aggregates of greater than 20 (Group 3). There was a highly significant difference in complete remission rates between Group 3 and the other two groups (p less than 0.001). Linear logistic regression analysis demonstrated the independence of the growth in vitro from other prognostic variables. A predictive model utilizing the in vitro result more accurately predicted for remission, both retrospectively and prospectively, than a model constructed with presently known prognostic parameters. The cause of death in failures suggested that this system detects resistance to the chemotherapy.

Entities:  

Mesh:

Year:  1976        PMID: 1069596

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex.

Authors:  M Beran; B Andersson; S Eksborg; H Ehrsson
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

2.  Cellular aggregates in bone marrow cultures of patients with acute myeloid leukemia.

Authors:  R E Merchant; M R Müller
Journal:  Blut       Date:  1982-06

3.  To early distinguish neonatal transient leukemoid proliferation from congenital leukemia by in vitro cell growth.

Authors:  D C Liang; E Y Shen; S C Chyou
Journal:  Blut       Date:  1986-08

4.  Growth and differentiation patterns of human acute non lymphoid leukemia in diffusion chambers before and after treatment.

Authors:  T Izzi; A Fontebuoni; G Lucarelli
Journal:  Blut       Date:  1981-07

5.  Marrow culture studies in adult acute myeloid leukemia at diagnosis and during complete remission.

Authors:  L Y Shih; C Y Chang
Journal:  Blut       Date:  1985-04

Review 6.  Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies.

Authors:  Leopold Ohler; Klaus Geissler; Wolfgang Hinterberger
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

7.  Relation of in vitro growth characteristics to cytogenetics and treatment outcome in acute myeloid leukemia: prognostic significance in patients with a normal karyotype.

Authors:  Andrea Berer; Birgit Kainz; Ulrich Jäger; Eva Jäger; Susanna Stengg; Berthold Streubel; Christa Fonatsch; Gerlinde Mitterbauer; Klaus Lechner; Klaus Geissler; Leopold Ohler
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

8.  Maturation and proliferation capacity of blood cells from untreated acute myeloid leukemia and its prognostic significance.

Authors:  K M Koeppen; I T Boll
Journal:  Klin Wochenschr       Date:  1978-08-01

9.  Serum thymidine kinase in acute leukaemia.

Authors:  H Hagberg; S Gronowitz; A Killander; C Källander; B Simonsson; C Sundström; G Oberg
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

10.  Human myeloid leukaemic cell interactions in vitro with normal myeloid colonies.

Authors:  G Spitzer; D S Verma; M Beran; A R Zander; K A Dicke; K B McCredie; S Siegel; S Tindle
Journal:  Br J Cancer       Date:  1981-02       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.